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Background: Ecto-5’-nucleotidase (CD73) plays an important role in the development of several types of cancer; 
however, its prognostic significance in salivary gland tumors remains unknown. The current study was conducted 
to investigate the expression of CD73 in such tumors. 
Material and Methods: In this retrospective study, immunohistochemical expression of CD73 was evaluated in 
25 pleomorphic adenomas, 20 mucoepidermoid carcinomas and 20 adenoid cystic carcinomas using the Envision 
technique. Labeling indices of CD73 expression were calculated and compared between lesions.  
Results: Immunohistochemical analysis demonstrated that the CD73 expression was significantly higher in salivary 
gland tumors than in normal salivary gland tissue (p<0.001). CD73 expression was significantly higher in mucoepi-
dermoid carcinoma and adenoid cystic carcinoma compared to pleomorphic adenoma p<0.001). In addition, the 
expression of CD73 was significantly higher in lymph node metastasizing cancers compared to non-metastasizing 
malignancies (P<0.001). In contrast, there was no significant association between CD73 expression and other cli-
nicopathological variables such as age, gender, tumor size and distant metastasis (P>0.05). 
Conclusions: The findings suggest that CD73 can be an independent and useful biomarker for predicting the clinical 
behavior of salivary gland tumors.




Ecto-5’-nucleotidase (ecto-5’-NT; CD73) is a glycosyl 
phosphatidylinositol-anchored cell surface protein 
which converts extracellular 5’-AMP to adenosine by 
dephosphorylation of AMP (1). CD73 plays various cru-
cial roles in physiological and pathophysiological pro-
cesses, including inflammation (2), hepatic fibrosis (3), 
renal function (4), myocardial ischemia (5), hypoxia, 
vascular permeability (6) and platelet function (7).
In addition to its serving as an enzyme, CD73 has been 
found to be over expressed in several types of human 
and mouse cancers such as breast (8), gastric (9), pan-
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creatic (10), ovarian (11), melanoma (12) and bladder 
malignancy (13). The clinical significance of this ubi-
quitous protein and its association with outcome and 
prognosis of cancers has already been demonstrated 
(14). Recently, some studies have revealed that CD73 
is a key regulatory molecule of tumor cells and is upre-
gulated in certain malignancies; therefore, it has been 
suggested that the expression of CD73 is associated with 
tumor growth, angiogenesis, invasion, metastasis and 
other characteristics of cancerous tissues (15-25), but 
the mechanisms involved in such associations have not 
yet been determined.   
Although the expression of this protein has been de-
monstrated in many types of cancer, little research has 
been conducted on the prognostic and diagnostic value 
of CD73 in oral and maxillofacial tumors to date.
Ren et al. evaluated the immunohistochemical expres-
sion of CD73 in oral squamous cell carcinoma (OSCC) 
and showed the association of this marker with clini-
copathological characteristics of such patients, and su-
ggested that CD73 was a potential prognostic marker 
for OSCC (16). However, there are no reports available 
regarding the predictive ability of CD73 expression in 
tumor cells in patients with salivary gland tumors.
Salivary gland neoplasms comprise approximately 5% 
of head and neck tumors (27). The diagnosis of such rare 
pathologies is often not straightforward. The overlap-
ping features of different types of salivary gland tumors 
may present a diagnostic challenge for oral pathologists 
and surgeons (28). The most common benign salivary 
gland tumor is pleomorphic adenoma; and mucoepider-
moid carcinoma and adenoid cystic carcinoma are the 
most prevalent malignant tumors (29). Assessment of 
salivary gland neoplasms using histopathological eva-
luation by hematoxylin-eosin (H&E) staining is someti-
mes difficult. Therefore, for definite diagnosis, in addi-
tion to H&E staining, other molecular technique such as 
immunohistochemistry (IHC) is advised to differentiate 
these similar tumors (30). 
Therefore, the current study aimed to evaluate the ex-
pression and prognostic significance of CD73 in com-
mon salivary gland tumors and also investigate the va-




A total of 65 cases of primary salivary gland tumor were 
selected from the existing records in the pathology labo-
ratory of Khalili Hospital, Shiraz University of Medical 
Sciences. There were 20 cases of mucoepidermoid car-
cinoma (MEC), 20 cases of adenoid cystic carcinoma 
(Adcc), and 25 cases of pleomorphic adenoma (PA). 
Re-evaluation of H&E-stained sections was performed 
to confirm the diagnosis and then the cases with adequa-
te cellular tissue were selected for IHC evaluation. The 
control group consisted of 55 cases with normal salivary 
gland tissue. Clinical information including the age and 
gender of the patients as well as the location of the tu-
mors was collected from the patient’s medical files.
-Immunohistochemical method
Paraffin-embedded material was cut into 4μm-thick sec-
tions and mounted on poly-L-lysine- coated slides. The 
sections were deparaffinized with xylen, rehydrated in 
graded alcohols and washed in distilled water. Antigen 
retrieval was performed by the application of pepsin en-
zyme at 35-40°C for 12 minutes. Endogenous peroxida-
se activity was blocked following a 5-minute incubation 
period with 3% hydrogen peroxide. Then, the sections 
were incubated with anti-CD37 antibody (1:100 dilu-
tion; abcam (ab91086), Cambridge, MA, USA) for 30 
minutes. 3, 3 diamino benzidine (DAB liquid, DAKO 
Corporation, Denmark) was used as chromogen. Lung 
carcinoma tissues were used as positive control whilst 
omission of the primary antibody was considered as ne-
gative control.
The slides were assessed under a light microscope 
(Olympus CX31; Tokyo, Japan) at 400× magnification. 
CD73 staining was analyzed according to the percenta-
ge and intensity of stained cells. For this purpose, 1000 
epithelial cells were counted in 5 different fields at 40× 
magnification. Labeling index (LI) was calculated based 
on the number of immunostained cells to represent the 
percentage of CD73 immunopositive cells. In addition, 
intensity of staining was classified into four different 
categories consisting of: 0 (lack of staining), 1 (weak 
staining), 2 (moderate staining) and 3 (intense staining). 
-Statistical analysis
The results were analyzed using SPSS version 20.0. 
Mann-Whitney test, Kruskal Wallis test, Chi-Square 
test, Spearman´s correlation coefficient and receiver 
operating characteristic (ROC) curve test were used to 
compare the results between the groups and to find the 
association with clinicopathological features such as 
age, gender, tumor size, tumor grade, metastasis to lym-
ph nodes and distant metastasis. Differences were consi-
dered statistically significant at p<0.05.
Results
The demographic data of the patients are shown in Table 
1. The age range of the patients was 27-72 years. Im-
munohistochemical analysis showed that in the salivary 
gland tumors 63 (97%) of 65 cases were CD73-positive, 
while in the control group, 2 (3.6%) of 55 cases were 
CD73-positive. Therefore, salivary gland tumors revea-
led significantly higher expression of CD73 than normal 
salivary gland tissue (P < 0.001). Immunoreactivity was 
detected in the cytomembrane of epithelial cells. Mo-
reover, this marker exhibited a partial positive staining 
in the cytoplasm. 










Location Female Male 
Pleomorphic adenoma (PA) 25 14 11 44.3 (27-68) 20 PG, 5 MSG 
Mucoepidermoid carcinoma 
(MEC) 
20 11 9 58.2 (47-79) 11 PG, 7 SMG, 2 
MSG 
Adenoid cystic carcinoma 
(Adcc) 
20 10 10 56.7 (45-64) 8 PG, 12 SMG 
Total 65 35 30 53.6 (27-79) 39 PG, 19 SMG, 7 
MSG 
Table 1: Average age and gender of patients and location of salivary gland tumor.
PG, parotid gland; SMG, sub mandibular gland; MSG, minor salivary gland.
-Mucoepidermoid Carcinoma
All cases of MEC (including 4 low-grade, 10 intermedia-
te-grade and 6 high-grade tumors) exhibited immunore-
activity of CD73 and showed staining in the squamous 
and some of the intermediate cell components (Fig. 1). 
The LI ranged from 40%-80%. There was a significant 
difference between LI of low-grade MECs (mean, 45± 
16.8), intermediate-grade MECs (46.5±16.33) and hi-
gh-grade MECs (65±17.3) (p =0.04).
Fig. 1: Cytoplasmic and membranous expression of CD73 in Muco-
epidermoid carcinoma (×200).
-Adenoid Cystic Carcinoma
The tumors of Adcc consisted of 2 cases of the tubular 
subtype, 5 cases of the solid subtype and 13 cases of 
the cribriform subtype. All cases of Adcc were positi-
ve for CD73. The range of CD73 LI was 30-70%. The 
stain was seen in both ductal and myoepithelial compo-
nents (Fig. 2). The difference in LI between solid (mean: 
60±14.4), cribriform (mean: 40.63±11.7) and tubular 
(mean: 34±10.83) variants of Adcc was not statistically 
significant (P=0.1).
Fig. 2: Cytoplasmic and membranous expression of CD73 in Ad-
enoid cystic carcinoma (×200).
-Pleomorphic Adenoma
Out of 25 cases of PA, 23 demonstrated immunoreaction 
to CD73. The immunoreactivity was seen in both epi-
thelial and myoepithelial components (Fig. 3). The LI 
ranged from 0-20%. 
Fig. 3: Cytoplasmic and membranous expression of CD73 in pleo-
morphic adenoma (×200).
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The difference in the expression of CD73 between ma-
lignant and benign salivary gland tumors was also exa-
mined. The LI of CD73 was significantly lower in PA 
compared to MEC and AdCC (p<0.001) (Table 2). In ad-
dition, the difference of intensity of CD73 staining was 
statistically significant between malignant and benign 
tumors (p<0.001) (Table 3). No significant difference in 
CD73 LI was seen between the malignant tumors, but 
the overexpression of CD73 increased in MEC com-
pared to Adcc (p=0.11). Statistically, the expression of 
CD73 was significantly higher in samples with lymph 
node metastasis compared with those without metasta-
sis (P<0.001). In contrast, there was no significant as-
sociation between CD73 expression and other clinico-
pathological variables such as age, gender, tumor size 
and distant metastasis (P>0.05). (Table 4) According to 
the receiver operating characteristic (ROC) curve, we 
obtained a cut-off point of 22.5 % for CD73 (sensitivi-
ty: 97.3%, specificity: 100%) to discern between benign 
and malignant salivary gland tumors.
Discussion
Current evidence reveals that IHC plays a crucial role 
in the diagnosis of salivary gland tumors; this important 
but limited method should be carried out after detailed 
examination for cancer using H&E staining. Indeed, 
IHC can be performed to facilitate and support the his-
tiopathological evaluation for definitive diagnosis (30). 
To the best of our knowledge, the current work is the first 
study to evaluate CD73 immunoexpression in benign 
and malignant salivary gland tumors. The present study 
clearly showed higher expression of CD73 in salivary 
gland tumors than normal salivary gland tissue. This re-
sult confirms that CD73 is a key regulatory molecule in 
the tumorogenesis process of these tumors. In addition, 
the present results revealed that CD73 expression was 
significantly higher in malignant salivary gland tumors 
than benign salivary gland tumors (p=0.000). 
The available findings on CD73 immunoreactivity in 
other tumors support our findings. Association of high 
expression of CD73 with poor prognosis of colorec-
tal cancers was reported previously, and the biological 
properties of CD73 for identification of patients with 
progressive tumors were demonstrated (15,16). Addi-
tionally, another study investigated the expression of 
CD73 in patients with adenocarcinoma of gallbladder 
and revealed that CD73 overexpression was associated 
with tumor progression and survival time of patients. 
That study also showed that CD73 was an independent 
marker for the prognosis and clinical behaviors of gall-
bladder adenocarcinoma (19).
Furthermore, we found that the CD73 expression was 
higher in lymph node metastasizing salivary gland can-
cers than non-metastasizing ones. In agreement with our 
finding, some studies have demonstrated that expres-
sion of CD73 may be associated with tumor promotion 
and this enhances the metastatic feature of cancer cells 
(31,32). These retrospective studies exhibited that CD73 
Salivary gland tumor Number of specimen Mean±SD P value 
MEC 20 51.75±18.15  
<0.001 Adcc 20 42.75±14.55 
PA 25 9.8± 6.37 
Total 65 32.84±22.92 
	
Table 2: Labeling index (LI) of CD73 in the three types of salivary gland tumors.
MEC, mucoepidermoid carcinoms; Adcc, adenoid cystic carcinoma; PA, pleomorphic adenoma.
	
Tumor type Frequency based on intensity of staining P value 
 No staining (0) Week (1) Moderate (2) Intense (3)  
 
<0.001 
MEC 0 1 1 18 
Adcc 0 2 1 17 
PA 2 4 14 5 
Table 3: Intensity of staining in the three types of salivary gland tumors (n = 65).
MEC, mucoepidermoid carcinoms; Adcc, adenoid cystic carcinoma; PA, pleomorphic adenoma.
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Variable              No. (%) Mean LI of CD73 (Mean±SD) P value 
Gender  
Male                     29 (44.6)  







<65                      43 (66.1) 







N0                         45 (69.2) 







T1+T2                  40 (61.5) 







M0                       62 (95.3) 






Table 4: Association between clinicopathological characteristics and CD73 expression in patients 
with salivary gland tumors.
LI, labeling index; N, lymphnode metastasis; T, tumor size; M, distant metastasis.
contributed to metastasis of prostate cancer, gastric can-
cer and malignant melanoma (12,18,23).
In contrast, there are a number of reports regarding the 
correlation of CD73 with improved clinical outcome in 
patients with different solid tumors. A study evaluating 
the biological role of CD73 in breast cancer showed that 
increased expression of CD73 could serve as a potential 
diagnostic marker for breast carcinoma with good prog-
nosis (24). Another study considering the expression of 
CD73 in epithelial ovarian carcinoma showed higher 
expression of CD73 in patients with favorable progno-
sis. Associations of CD73 overexpression with better 
prognosis, lower stage and better differentiation were 
demonstrated in this study (17). 
However, there are other investigations in agreement with 
our observations regarding CD73 expression in prostate, 
gastric and certain types of breast cancer (18,23,25). In-
consistent results considering the role of CD73 in diffe-
rent solid tumors could be explained by the fact that diffe-
rent tissues have various enzymatic activity of CD73 (33). 
The present work was a retrospective study with a small 
sample size. Therefore, randomized prospective studies 
with a larger sample size should be conducted to support 
our results. Moreover, other molecular studies are nee-
ded to support the idea that CD73 is a prognostic and 
diagnostic marker in salivary gland tumors. 
Conclusions
In the present study, overexpression of CD73 was ob-
served in malignant salivary gland tumors. Therefore, 
in addition to the known prognostic parameters, CD73 
may serve as a potential biological marker to differen-
tiate malignant and benign salivary gland tumors. Mo-
reover, based on the findings of this study, there was a 
positive relation between the expression of CD73 and 
lymph node metastasis. Therefore, immunohistochemi-
cal analysis of CD73 may help clinicians to predict the 
biological behavior of salivary gland malignancies.
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